Geneva, Switzerland and Boston, MA – February 27, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
Month: February 2020
ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020
Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern
Pohl O., Marchand L., Bell D., Gotteland JP.
ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020
Geneva, Switzerland and Boston, MA – February 18, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing…